machine learning Feb 13, 2023 Sophia Genetics, AstraZeneca Add Multimodal Approach to Cancer Drug Development Partnership Jan 25, 2023 Indivumed Sells Biospecimens Service Unit to CRO Crown Bioscience Dec 15, 2022 Pangea Biomed Nets Additional $5M in Seed Funds Dec 13, 2022 Envisagenics, Cancer Research UK, Queen Mary University Collaborate on AML Drug R&D Nov 14, 2022 Cota, Google Cloud to Codevelop NLP Algorithms to Mine Unstructured Oncology Data Nov 1, 2022 OncoPrecision Validating Patient-Derived Functional Drug Screening Platform Oct 7, 2022 Swiss Biotech PreComb Therapeutics Wants to Automate Functional Precision Medicine Premium Oct 5, 2022 Massive Bio, Perthera Partner on Biomarker-Based Clinical Trial Matching Sep 30, 2022 Meliora Therapeutics Raises $11M in Seed Financing Sep 22, 2022 Persephone Biosciences Enrolls First Patient in Study of Microbiome Effect on Cancer Drug Response Jul 14, 2022 Nilogen Oncosystems, Scailyte Partner to Improve Precision Cancer Drug Development Jun 22, 2022 Mark Foundation, Johns Hopkins University Invest $10M in Cancer Immunotherapy Research Jun 15, 2022 Imagia Canexia Health Garners CE-IVD Mark for Comprehensive Cancer Testing Platform May 23, 2022 Qlucore Expands Into Bladder Cancer Diagnostics With Lund University Partnership May 10, 2022 OncoHost Raises $35M in Series C Financing Apr 7, 2022 Pangea Biomed Builds on RNA-Based Drug Matching to Expand Precision Oncology Opportunities Premium Mar 3, 2022 Known Medicine, Duke University Partner to Study Predictive Platform for Lung Cancer Drug Response Feb 28, 2022 Inhibrx, Genialis Partner to Identify Predictive Biomarker for INBRX-109 Feb 23, 2022 American Oncology Network, VieCure Ink Precision Oncology Partnership Feb 15, 2022 Lantern Pharma Working With Greehey Children's Cancer Research Institute To ID New Uses for Drugs Load More Breaking News Flare Therapeutics Raises $123M in Oversubscribed Series B Funding Round William Blair Initiates Coverage of MDxHealth With Outperform Rating White House Report Outlines Goals to Advance Genomic Research, Precision Therapy Development In Brief This Week: Fore Biotherapeutics, RayzeBio, Gilead Sciences, Atossa Therapeutics Bayer to Assess Nubeqa in High-Risk, Early-Stage Hormone-Sensitive Prostate Cancer BridgeBio Begins Phase I/II Study of SHP2 Inhibitor, Opdivo in KRAS-Mutant Solid Tumors